Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Fransen

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder CancerSarah M H Einerhand, Charlotte S Voskuilen, Elies E Fransen van de Putte, et al.
Urologic Oncology|September 3, 2015
Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized templateElisabeth E Fransen van de Putte, Tom J N Hermans, Erik van Werkhoven, et al.
World Journal of Urology|July 18, 2015
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatinElisabeth E Fransen van de Putte, Laura S Mertens, Richard P Meijer, et al.
Human Molecular Genetics|July 13, 1999
High prevalence of symptoms of Menière's disease in three families with a mutation in the COCH geneE Fransen, M Verstreken, W I Verhagen, et al.
The Journal of Urology|November 25, 2015
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?Daan J Reesink, Elisabeth E Fransen van de Putte, Erik Vegt, et al.
World Journal of Urology|June 19, 2017
Dose dense MVAC prior to radical cystectomy: a real-world experienceHomayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, et al.
European Urology Open Science|September 11, 2023
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?Elisabeth E Fransen van de Putte, Luna van den Brink, Mohamed A Mansour, et al.
Journal of Medical Genetics|August 3, 2001
A common founder for the 35delG GJB2 gene mutation in connexin 26 hearing impairmentL Van Laer, P Coucke, R F Mueller, et al.
Clinical Genitourinary Cancer|June 10, 2018
Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder TumorsJudith Bosschieter, Anouk Hentschel, C Dilara Savci-Heijink, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2016
Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based studyTom J N Hermans, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder CancerSarah M H Einerhand, Charlotte S Voskuilen, Elies E Fransen van de Putte, et al.
Urologic Oncology|September 3, 2015
Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized templateElisabeth E Fransen van de Putte, Tom J N Hermans, Erik van Werkhoven, et al.
World Journal of Urology|July 18, 2015
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatinElisabeth E Fransen van de Putte, Laura S Mertens, Richard P Meijer, et al.
Human Molecular Genetics|July 13, 1999
High prevalence of symptoms of Menière's disease in three families with a mutation in the COCH geneE Fransen, M Verstreken, W I Verhagen, et al.
The Journal of Urology|November 25, 2015
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?Daan J Reesink, Elisabeth E Fransen van de Putte, Erik Vegt, et al.
World Journal of Urology|June 19, 2017
Dose dense MVAC prior to radical cystectomy: a real-world experienceHomayoun Zargar, Jay B Shah, Elisabeth E Fransen van de Putte, et al.
European Urology Open Science|September 11, 2023
Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?Elisabeth E Fransen van de Putte, Luna van den Brink, Mohamed A Mansour, et al.
Journal of Medical Genetics|August 3, 2001
A common founder for the 35delG GJB2 gene mutation in connexin 26 hearing impairmentL Van Laer, P Coucke, R F Mueller, et al.
Clinical Genitourinary Cancer|June 10, 2018
Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non-muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder TumorsJudith Bosschieter, Anouk Hentschel, C Dilara Savci-Heijink, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2016
Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based studyTom J N Hermans, Elisabeth E Fransen van de Putte, Simon Horenblas, et al.
Pageof 13